Talk:1-Amino-5-phosphonoindan-1-carboxylic acid

Requested move 25 December 2023

 * The following is a closed discussion of a requested move. Please do not modify it. Subsequent comments should be made in a new section on the talk page. Editors desiring to contest the closing decision should consider a move review after discussing it on the closer's talk page. No further edits should be made to this discussion.

The result of the move request was: Moved to 1-Amino-5-phosphonoindan-1-carboxylic acid. Consensus on the alternative. – robertsky (talk) 00:10, 11 January 2024 (UTC)

APICA (drug) → APICA (metabotropic glutamate receptor antagonist) – The current title is ambiguous with, and the other one attracts around 7&times; the pageviews. —⁠ ⁠BarrelProof (talk) 03:32, 25 December 2023 (UTC) — Relisting. – robertsky (talk) 17:37, 2 January 2024 (UTC)


 * Comment does the DAB tag need to be that long? Would prefer a shorter one, but if not, would still support the proposed .  Dank Jae  02:01, 29 December 2023 (UTC)
 * I considered APICA (receptor antagonist), but both topics seem to fit that description. How about ? —⁠ ⁠BarrelProof (talk) 03:03, 29 December 2023 (UTC)
 * I guess best to do the full name, 1-Amino-5-phosphonoindan-1-carboxylic acid, as 2-Methyl-6-(phenylethynyl)pyridine a similar one uses the full name because MPEP isn't primarily used for it nor links to it. But maybe still make the initial proposed title a redirect. Ofc, should APICA be more used for this one, then that could be considered in the future.  Dank Jae  20:28, 4 January 2024 (UTC)
 * Relisting comment: on the alternatives? – robertsky (talk) 17:37, 2 January 2024 (UTC)
 * Clarify, Move to 1-Amino-5-phosphonoindan-1-carboxylic acid.  Dank Jae  04:05, 9 January 2024 (UTC)

The discussion above is closed. Please do not modify it. Subsequent comments should be made on the appropriate discussion page. No further edits should be made to this discussion.